

DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

June 18, 2020

MO HealthNet

Meeting via WebEx only

Meeting number (access code): 283 092 818

Join from a video system or application

Dial [283092818@stateofmo.webex.com](tel:283092818)

You can also dial 173.243.2.68 and enter your meeting number.

Join by phone

Tap to call in from a mobile device (attendees only)

[1-650-479-3207](tel:16504793207) Call-in toll number (US/Canada)

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 – 10:35	DUR Update	Josh Moore
<u>Old Business</u>		
10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
<u>New Business</u>		
10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Josh Moore
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. PDL Agents	
	iv. Prior Authorization	
11:00 – 11:45	Clinical Edits	Josh Moore
	Discussion, Public Hearing and Decision will be held for each edit.	
	i. Ampyra	
	ii. Crysvida	
	iii. Diacomit	
	iv. Gamifant	
	v. Iron, Injectable	
	vi. Koselugo	
	vii. Luxturna	
	viii. Orilissa	
	ix. Oxervate	
	x. Palynziq	
	xi. Parathyroid Hormone & Bone Resorption Suppression Related Agents	
	xii. Reblozyl	
	xiii. Synagis	
	xiv. Tepezza	
	xv. Tolvaptan	
	xvi. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors	

Preferred Drug List (PDL)

Discussion, Public Hearing and Decision will be held for each edit.

- i. Alpha-Glucosidase Inhibitors
- ii. Amylin Analogs
- iii. Antibiotics, GI, Oral Agents
- iv. Antibiotics, Vaginal Agents
- v. Antihyperuricemic Agents
- vi. Anti-Migraine, Alternative Oral Agents
- vii. Benign Prostatic Hyperplasia Agents
- viii. Biguanides & Combination Agents
- ix. Bile Salt Agents
- x. Bone Ossification Agents
- xi. Cephalosporins
- xii. Colony Stimulating Factors
- xiii. Cryopyrin-Associated Periodic Syndrome (CAPS) Agents
- xiv. DPP-IV Inhibitors & Combination Agents
- xv. Electrolyte Depleters – Phosphate Lowering Agents
- xvi. Electrolyte Depleters – Potassium Lowering Agents
- xvii. Erythropoiesis Stimulating Agents
- xviii. Fluoroquinolones, Oral Agents
- xix. GLP-1 Receptor Agonists & Combination Agents
- xx. Growth Hormones, Somatropin Agents
- xxi. Growth Hormones & Growth Hormone Releasing Factors – Select Agents
- xxii. Hepatitis C Agents
- xxiii. Insulins, Long-Acting
- xxiv. Insulins, Mixed
- xxv. Insulins, Non-Analogs
- xxvi. Insulins, Rapid-Acting
- xxvii. Macrolides
- xxviii. Meglitinides
- xxix. Methotrexate Agents
- xxx. Multiple Sclerosis, Injectable Agents
- xxxi. Multiple Sclerosis, Oral Agents
- xxxii. Penicillins
- xxxiii. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors & Combination Agents
- xxxiv. Sulfonylureas, 2nd Generation
- xxxv. Targeted Immune Modulators, IL-17A Antibody/IL-17 Receptor Antagonists & IL-23/IL-12 Inhibitors
- xxxvi. Targeted Immune Modulators, IL-6 Receptor Inhibitors
- xxxvii. Targeted Immune Modulators, Janus Kinase (JAK) Inhibitors
- xxxviii. Targeted Immune Modulators, Select Agents
- xxxix. Targeted Immune Modulators, Tumor Necrosis Factor (TNF) Inhibitors
- xl. Tetracyclines
- xli. Thiazolidinediones (TZD) & Combination Agents
- xl.ii. Thrombocytopenia Agents
- xl.iii. Urinary Tract Antispasmodics

- 1:00 – 1:15 **LUNCH**
- 1:15 – 1:30 **Program Utilization Information – Conduent Update** Olivia Rush
- i. Call Center Statistics
 - ii. CyberAccess User Statistics
 - iii. New Drug Statistics
 - iv. “Top 25” Drugs by Cost/Claims
- 1:30 – 1:50 **Other Business**

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.

NEXT MEETING: September 17, 2020
Department of Natural Resources
1101 Riverside Dr., Jefferson City, MO 65101
Lacharette/Nightingale Rooms